Charles Johnson, MD
Dr Johnson, was named interim CMO of Enterprise Therapeutics in October of 2018. Dr. Johnson was most recently Chief Medical Officer at Neurotech Pharmaceuticals. Prior to this, he held leadership positions at Vertex Pharmaceuticals, Inspire Pharmaceuticals and APT Pharmaceuticals. At Vertex for 5 years he held the position Vice President Global Medical Affairs. During his 13 year tenure at Genentech, he lead the Immunology and Tissue Repair clinical group with responsibility for the approvals of LUCENTIS® for wet age-related macular degeneration, RITUXAN® for rheumatoid arthritis and XOLAIR® for severe allergic asthma. Dr. Johnson received his medical degree from the University of Cape Town in South Africa, attained Board Certification in Pediatrics at the Red Cross War Memorial Children’s Hospital. He spent six years at Washington University in Saint Louis as Center Director of the Cystic Fibrosis Center at the Children’s Hospital before joining industry.